Value of Pyrazinamide for Composition of New Treatment Regimens for Multidrug-Resistant Mycobacterium Tuberculosis in China

BMC Infectious Diseases - United Kingdom
doi 10.1186/s12879-020-4758-9
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Revolutionary New Treatment Regimens for Multidrug-Resistant Tuberculosis

The Lancet Infectious Diseases
Infectious Diseases
2019English

Pyrazinamide May Improve Fluoroquinolone-Based Treatment of Multidrug-Resistant Tuberculosis

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2012English

Bedaquiline: New Approach for Treatment of Multidrug-Resistant Tuberculosis

RUHS Journal of Health Science
2019English

Treatment Outcomes of Rifabutin-Containing Regimens for Rifabutin-Sensitive Multidrug-Resistant Pulmonary Tuberculosis

International Journal of Infectious Diseases
MedicineInfectious DiseasesMicrobiology
2017English

Clofazimine for the Treatment of Multidrug-Resistant Tuberculosis

Clinical Microbiology and Infection
MedicineInfectious DiseasesMicrobiology
2019English

Reply to Anthony Et Al., “Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment”

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2017English

Multidrug-Resistant Mycobacterium Tuberculosis: Molecular Perspectives

Emerging Infectious Diseases
EpidemiologyInfectious DiseasesMicrobiology
1998English

Characterization of pncA Mutations in Pyrazinamide-Resistant Mycobacterium Tuberculosis in Brazil

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2005English

Shorter Regimens for Multidrug-Resistant Tuberculosis Should Also Be Applicable in Europe

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy